CHF Solutions to Host Webinar Discussing Treatment of Fluid Overload in Pediatric Patients
June 23 2020 - 8:00AM
CHF Solutions (Nasdaq: CHFS) today announced the company will host
an interactive, physician-led webinar to discuss treatment of fluid
overload in pediatric patients greater than 20 kg. Registration is
open for the webinar, which will be led by Dr. David Askenazi, M.D.
MSPH and will take place on July 9 at 1:00 p.m. EDT.
Fluid overload is associated with significant increases in
morbidity and mortality in pediatric patients. Maintaining fluid
balance while assuring hemodynamic stability in critically ill
pediatric patients is crucial to reduce the risk of morbidity and
mortality. Diuretics and traditional CRRT devices are not always
optimal for pediatric patients with fluid overload.
The Aquadex SmartFlow™ System is used to remove excess fluid
precisely and gently in a way that maintains stable blood flow in
the heart and vessels (hemodynamic stability). A retrospective,
multi-center study of 32 critically ill pediatric patients showed
that 97% of these patients survived to the end of therapy when
their fluid overload was treated with the Aquadex system.1
David Askenazi, M.D. MSPH, Director Pediatric and Infant Center
for Acute Nephrology (PICAN) University of Alabama Birmingham
Children’s of Alabama, is a forerunner in pediatric renal support
therapy and author of dozens of clinical papers on managing fluid
balance and providing kidney support in pediatric patients. He has
created and hosts the Neonatal and Infant Course on Kidney Support
(NICKS) at Children’s of Alabama.
“Ultrafiltration therapy is an effective solution for the
underserved pediatric patients suffering from fluid overload,” said
John Erb, CEO of CHF Solutions. “We appreciate Dr. Askenazi’s
willingness to share his experience and continue to provide
valuable medical education to pediatricians.”
Register to participate in this webinar:
https://zoom.us/webinar/register/WN_h0DXc_s-TUOdg602RaCiNg
About CHF Solutions CHF Solutions, Inc. (CHFS)
is a medical device company dedicated to changing the lives of
patients suffering from fluid overload through science,
collaboration, and innovation. The company is focused on
developing, manufacturing and commercializing the Aquadex
SmartFlow™ system for ultrafiltration therapy. CHF Solutions is
headquartered in Minneapolis, Minn., with wholly-owned subsidiaries
in Australia and Ireland. The company has been listed on the Nasdaq
Capital Market since February 2012.
About the Aquadex SmartFlow System The Aquadex
SmartFlow system delivers clinically proven therapy using a simple,
flexible and smart method of removing excess fluid from patients
suffering from hypervolemia (fluid overload). The Aquadex SmartFlow
system is indicated for temporary (up to 8 hours) or extended
(longer than 8 hours in patients who require hospitalization) use
in adult and pediatric patients weighing 20 kg or more whose fluid
overload is unresponsive to medical management, including
diuretics. All treatments must be administered by a health care
provider, within an outpatient or inpatient clinical setting, under
physician prescription, both having received training in
extracorporeal therapies.
Forward-Looking Statements Certain statements
in this release may be considered forward-looking statements within
the meaning of the Private Securities Litigation Reform Act of
1995, including without limitation, statements about the treatment
of fluid overload in pediatric patients. Forward-looking statements
are predictions, projections and other statements about future
events that are based on current expectations and assumptions and,
as a result, are subject to risks and uncertainties. Many factors
could cause actual future events to differ materially from the
forward-looking statements in this release, including, without
limitation, those risk associated with our ability to execute on
our commercial strategy, the possibility that we may be unable to
raise sufficient funds necessary for our anticipated operations,
our post-market clinical data collection activities, benefits of
our products to patients, our expectations with respect to product
development and commercialization efforts, our ability to increase
market and physician acceptance of our products, potentially
competitive product offerings, intellectual property protection,
our ability to integrate acquired businesses, our expectations
regarding anticipated synergies with and benefits from acquired
businesses, and other risks and uncertainties described in our
filings with the SEC. Forward-looking statements speak only as of
the date when made. CHF Solutions does not assume any obligation to
publicly update or revise any forward-looking statements, whether
as a result of new information, future events or otherwise.
1. https://cjasn.asnjournals.org/content/early/2019/08/27/CJN.03240319
CONTACTS
INVESTORS:
Claudia Napal Drayton
Chief Financial Officer, CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com
MEDIA:
Jessica Stebing
Health+Commerce
260-336-6202
jstebing@healthandcommerce.com
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Aug 2024 to Sep 2024
CHF Solutions (NASDAQ:CHFS)
Historical Stock Chart
From Sep 2023 to Sep 2024